Building in vivo Preclinical Assays of Circuit Engagement for Application in Therapeutic Development (R01 Clinical Trial Not Allowed)
ID: 345272Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Award Range

$0 - $250K

Eligible Applicants

Others

Funding Category

Health

Funding Instrument

Grant

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/345272

Additional Information

http://grants.nih.gov/grants/guide/pa-files/PAR-23-091.html
Timeline
    Description

    The National Institutes of Health (NIH) has announced a funding opportunity titled "Building in vivo Preclinical Assays of Circuit Engagement for Application in Therapeutic Development (R01 Clinical Trial Not Allowed)." This initiative aims to develop innovative neurophysiological and behavioral measures in animal models to enhance the early-phase therapeutic development for mental illnesses, addressing the challenges faced in novel treatment development over the past two decades. Successful applications must focus on optimizing these measures to reflect human assays, validating their sensitivity and selectivity through pharmacodynamic studies, and ensuring they are clinically relevant. The grant has an award ceiling of $250,000, with applications accepted until September 7, 2025. For further inquiries, interested parties can contact NIH Grants Information at grantsinfo@nih.gov or visit the opportunity's webpage at https://grants.nih.gov/grants/guide/pa-files/PAR-23-091.html.

    Point(s) of Contact
    grantsinfo@nih.gov
    Files
    Title
    Posted
    PAR-23-091-Full-Announcement.html
    PAR-23-091.html
    The Department of Health and Human Services, via the National Institutes of Health (NIH), has launched a funding opportunity titled "Building in vivo Preclinical Assays of Circuit Engagement for Application in Therapeutic Development (R01 Clinical Trial Not Allowed)." This initiative aims to develop innovative neurophysiological and behavioral measures in animals to enhance early-phase therapeutic development for mental illnesses. Recognizing the limited success in novel treatment development over the past two decades, this FOA seeks to identify biomarkers reflective of neural processes associated with mental health conditions. Successful applications must optimize these measures to mirror human assays, assess their sensitivity and selectivity through pharmacodynamic studies, and validate the underlying brain processes influencing behavior. Eligible applicants include academic institutions, nonprofits, and for-profit entities, with an open application period running until September 2025. Significantly, this opportunity discourages the use of human subjects and emphasizes the creation of clinically relevant, translational assays in animal models, contributing significantly to mental health research and therapeutic development pipelines.
    Similar Opportunities
    Building in vivo Preclinical Assays of Circuit Engagement for Application in Therapeutic Development (R01 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Building in vivo Preclinical Assays of Circuit Engagement for Application in Therapeutic Development (R01 Clinical Trial Not Allowed)" aimed at enhancing therapeutic development for mental illnesses. This initiative seeks to establish in vivo neurophysiological and behavioral measures that can serve as assays in the early screening phase of treatment development, focusing on optimizing and evaluating innovative measures that reflect neural processes relevant to both preclinical species and humans. The funding is particularly significant as it addresses critical gaps in the therapeutic development pipeline, with eligible applicants including various educational institutions and organizations, and a budget cap of $250,000 in direct costs per year. Interested parties must submit their applications by February 5, 2025, with a maximum project period of five years, and can direct inquiries to grantsinfo@nih.gov for further information.
    Novel Assays to Address Translational Gaps in Treatment Development (UG3/UH3 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Novel Assays to Address Translational Gaps in Treatment Development," aimed at developing neurophysiological assays to enhance treatment strategies for mental disorders. This initiative seeks to support partnerships among neuroscientists to optimize and evaluate pharmacodynamic measures in both human subjects and relevant animal models, thereby improving the efficiency of preclinical and clinical trials. The UG3/UH3 cooperative agreement format will facilitate a two-phase approach, focusing first on feasibility and assay optimization, followed by comparative performance evaluations. Interested applicants can find more information and submit proposals by June 20, 2025, and should direct inquiries to NIH Grants Information at grantsinfo@nih.gov.
    Novel Assays to Address Translational Gaps in Treatment Development (UG3/UH3 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is inviting applications for the "Novel Assays to Address Translational Gaps in Treatment Development" initiative, aimed at advancing neurophysiological measures that can serve as assays for drug and device therapies in mental health research. This funding opportunity encourages collaborative partnerships among neuroscientists to optimize in vivo testing in both preclinical species and humans, with a focus on bridging the gap between preclinical and clinical measures to enhance therapeutic outcomes for mental disorders. Eligible applicants include a wide range of organizations, such as higher education institutions, nonprofits, and foreign entities, with key deadlines including an application due date of January 21, 2025, and a funding expiration on June 21, 2025. For further inquiries, interested parties can contact NIH Grants Information at grantsinfo@nih.gov.
    Assay Development and Screening for Discovery of Validated Chemical Hits for Brain Disorders (R01 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Assay Development and Screening for Discovery of Validated Chemical Hits for Brain Disorders (R01 Clinical Trial Not Allowed)," aimed at advancing research in drug discovery for psychiatric disorders. The initiative focuses on the development and validation of screening assays to identify effective chemical hits for conditions such as depression, bipolar disorder, and schizophrenia, encouraging innovative approaches in mental health research. This grant opportunity is open to a wide range of eligible applicants, including higher education institutions and community-based organizations, with no budget limits and a maximum project period of five years. Interested parties can find more information and submit inquiries via the NIH Grants Information email at grantsinfo@nih.gov, with applications accepted until May 7, 2026.
    Utilizing Invasive Recording and Stimulating Opportunities in Humans to Advance Neural Circuitry Understanding of Mental Health Disorders (R21 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Utilizing Invasive Recording and Stimulating Opportunities in Humans to Advance Neural Circuitry Understanding of Mental Health Disorders (R21 Clinical Trial Optional)." This grant aims to support innovative research utilizing invasive neural recording methods to explore the neural circuitry associated with mental health disorders, focusing on high-risk applications that address significant gaps in knowledge regarding complex moods and cognitive behaviors. The initiative seeks to bridge basic neuroscience with applied mental health interventions, encouraging diverse research teams to utilize advanced methodologies. The estimated funding amount is capped at $200,000, with applications due by January 7, 2028. For further inquiries, interested applicants can contact NIH Grants Information at grantsinfo@nih.gov or visit the additional information link at https://grants.nih.gov/grants/guide/pa-files/PAR-25-291.html.
    Utilizing Invasive Recording and Stimulating Opportunities in Humans to Advance Neural Circuitry Understanding of Mental Health Disorders (R01 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Utilizing Invasive Recording and Stimulating Opportunities in Humans to Advance Neural Circuitry Understanding of Mental Health Disorders (R01 Clinical Trial Optional)." This initiative aims to support invasive neural recording studies that investigate the neural circuitry and dynamics associated with mental health disorders, encouraging researchers to address specific questions with high translational potential. The program emphasizes the importance of innovative collaborations in neuroscience and engineering to enhance understanding and therapeutic approaches for mental health challenges. Applications will open on January 5, 2025, with a project duration of up to five years and no budget limits. Interested applicants can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries, and additional details can be found at the provided link: https://grants.nih.gov/grants/guide/pa-files/PAR-25-290.html.
    Assay Development and Screening for Discovery of Validated Chemical Hits for Brain Disorders (R01 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity for Research Project Grants (R01) aimed at the development of screening assays for drug candidates targeting psychiatric disorders. The primary objectives of this initiative are to stimulate research in the discovery and development of novel small molecules that can potentially treat mental illnesses, as well as to validate compounds that demonstrate desired biological activity through rigorous screening processes. This funding is crucial for advancing therapeutic options for conditions such as depression, schizophrenia, and PTSD, and it encourages applicants to align their proposals with the National Institute of Mental Health (NIMH) priorities. Interested applicants must submit their proposals by May 7, 2026, and can find additional information and application guidelines at the NIH grants website or contact NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    Discovery of in vivo Chemical Probes for the Nervous System (R01 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Discovery of in vivo Chemical Probes for the Nervous System (R01 Clinical Trial Not Allowed)" aimed at supporting research into novel small molecules that can modulate biological targets relevant to mental health, aging, drug abuse, and eye diseases. The initiative seeks to stimulate the discovery and development of in vivo chemical probes, requiring applicants to have validated starting compounds for optimization and bioassays to test new analogs. This funding is crucial for advancing the understanding of brain disease mechanisms and emphasizes projects that provide insights into significant biological processes. Interested applicants can submit proposals until January 7, 2027, with no budget limit specified, although actual needs must be indicated. For further inquiries, contact NIH Grants Information at grantsinfo@nih.gov, and additional details can be found at NIH Grants.
    Neuromodulation/Neurostimulation Device Development for Mental Health Applications (R21 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Neuromodulation/Neurostimulation Device Development for Mental Health Applications," aimed at advancing the development of innovative brain stimulation devices for mental health disorders. This initiative seeks applications that either create novel brain stimulation technologies or significantly enhance existing FDA-approved devices through improvements in hardware and software, focusing on increased spatiotemporal precision and multi-focal, closed-loop approaches. The program is particularly important for addressing limitations in current mental health treatments and fostering technological innovation in this field. Interested applicants can apply for grants up to $275,000 for a two-year project period, with applications due by January 7, 2028. For further inquiries, contact NIH Grants Information at grantsinfo@nih.gov or visit the additional information link at https://grants.nih.gov/grants/guide/pa-files/PAR-25-286.html.
    Neuromodulation/Neurostimulation Device Development for Mental Health Applications (R01 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Neuromodulation/Neurostimulation Device Development for Mental Health Applications (R01 Clinical Trial Not Allowed)" aimed at advancing the development of innovative brain stimulation devices for mental health treatment. This initiative seeks applications that either create novel devices or significantly enhance existing FDA-approved devices through hardware and software improvements, focusing on increased precision and effectiveness in treatment. The funding underscores the importance of multidisciplinary collaboration in neuroscience and engineering, with an emphasis on innovative approaches rather than incremental changes. Interested applicants can find more information and submit proposals by January 7, 2028, with no budget cap but a maximum project duration of five years. For inquiries, contact NIH Grants Information at grantsinfo@nih.gov or visit the opportunity's webpage at https://grants.nih.gov/grants/guide/pa-files/PAR-25-287.html.